Xenon Pharmaceuticals Inc Total Liabilities
Xenon Pharmaceuticals Inc total liabilities. Based on the latest financial reports, Xenon Pharmaceuticals Inc (XENE) has total liabilities worth $399.91 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Xenon Pharmaceuticals Inc defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Xenon Pharmaceuticals Inc (2012–2025)
Total liabilities of Xenon Pharmaceuticals Inc from 2012 to 2025. This chart illustrates how Xenon Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Check XENE financial resilience to evaluate the company's liquid asset resilience ratio.
Xenon Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Xenon Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Wesdome Gold Mines Ltd.
TO:WDO
|
Canada | CA$210.01 Million |
|
Kyndryl Holdings Inc
NYSE:KD
|
USA | $9.97 Billion |
|
Angel One Limited
NSE:ANGELONE
|
India | Rs-61.49 Billion |
|
OPT Machine Vision Tech Co. Ltd. A
SHG:688686
|
China | CN¥670.64 Million |
|
Guangzhou Haozhi Industrial Co Ltd
SHE:300503
|
China | CN¥1.71 Billion |
|
Cal-Maine Foods Inc
NASDAQ:CALM
|
USA | $467.04 Million |
|
FangDa Carbon New Material Co Ltd
SHG:600516
|
China | CN¥3.17 Billion |
|
Lisi S.A
PA:FII
|
France | €1.30 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down Xenon Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Xenon Pharmaceuticals Inc.
Liquidity & Leverage Metrics
Xenon Pharmaceuticals Inc Total Liabilities Ratios Explained
Xenon Pharmaceuticals Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.42 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.69 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Xenon Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Xenon Pharmaceuticals Inc (2012–2025)
The table below shows the annual total liabilities of Xenon Pharmaceuticals Inc from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $399.91 Million | +824.95% |
| 2024-12-31 | $43.24 Million | +17.24% |
| 2023-12-31 | $36.88 Million | +12.95% |
| 2022-12-31 | $32.65 Million | +48.58% |
| 2021-12-31 | $21.97 Million | +23.23% |
| 2020-12-31 | $17.83 Million | -68.00% |
| 2019-12-31 | $55.72 Million | +191.22% |
| 2018-12-31 | $19.13 Million | +87.82% |
| 2017-12-31 | $10.19 Million | +184.08% |
| 2016-12-31 | $3.59 Million | +23.02% |
| 2015-12-31 | $2.92 Million | -80.09% |
| 2014-12-31 | $14.64 Million | -51.80% |
| 2013-12-31 | $30.37 Million | -40.08% |
| 2012-12-31 | $50.68 Million | -- |
About Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizure… Read more